Expertise in
20
conditions

Dr. Cynthia Levy

Gastroenterology
Univ. Of Miami
1295 NW 14th St Ste A, 
Miami, FL 
Offers Telehealth
25 Years of Experience
Expertise in
20
conditions
Univ. Of Miami
1295 NW 14th St Ste A, 
Miami, FL 

Overview

Cynthia Levy is a Gastroenterologist in Miami, Florida. Dr. Levy has been practicing medicine for over 25 years is highly rated in 20 conditions, according to our data. Her top areas of expertise are Primary Biliary Cholangitis, Cholangitis, Sclerosing Cholangitis, Liver Transplant, and Pancreaticoduodenectomy.

Her clinical research consists of co-authoring 171 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in FL

Hospital Affiliations

Jackson Health System
Boca Raton Regional Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Univ. of Miami
1295 NW 14th St Ste A, Miami, FL 33125

Additional Areas of Focus

Dr. Levy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Bezafibrate, Obeticholic Acid
Study Phase: Phase 2
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: January 29, 2025
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Terminated
Publish Date: January 16, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC
A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC
Enrollment Status: Completed
Publish Date: April 24, 2024
Intervention Type: Drug
Study Drug: HTD1801 (BUDCA)
Study Phase: Phase 2
A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)
A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Unknown
Publish Date: April 22, 2024
Intervention Type: Drug
Study Drug: Sulfasalazine
Study Phase: Phase 2
Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C
Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Harvoni
Study Phase: Phase 2
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
Enrollment Status: Terminated
Publish Date: September 06, 2022
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 4
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
Enrollment Status: Completed
Publish Date: June 29, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 18 Less Clinical Trials

167 Total Publications

Comment on Ejaz et al. Letter to the Editor.
Comment on Ejaz et al. Letter to the Editor.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: October 30, 2025
Similar Doctors
Maria Abreu
Expertise in
9
conditions
Dr. Maria Abreu
Gastroenterology
Expertise in
9
conditions
Dr. Maria Abreu
Gastroenterology

Office

1475 NW 12th Ave Fl 1, 
Miami, FL 
 (0.7 miles away)
305-243-8644
Languages Spoken:
English
See accepted insurances

Maria Abreu is a Gastroenterologist in Miami, Florida. Dr. Abreu is highly rated in 9 conditions, according to our data. Her top areas of expertise are Ulcerative Colitis, Crohn's Disease, Viral Gastroenteritis, Colonoscopy, and Endoscopy.

Expertise in
53
conditions
Dr. Andres Gelrud
Gastroenterology
Expertise in
53
conditions
Dr. Andres Gelrud
Gastroenterology

Office

9408 SW 87th Ave Ste 200, 
Miami, FL 
 (12.5 miles away)
305-913-0666
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andres Gelrud is a Gastroenterologist in Miami, Florida. Dr. Gelrud is highly rated in 53 conditions, according to our data. His top areas of expertise are Hereditary Pancreatitis, Chronic Pancreatitis, Acute Pancreatitis, Pancreatectomy, and Endoscopy.

Eugene Schiff
Expertise in
9
conditions
Dr. Eugene Schiff
Gastroenterology
Expertise in
9
conditions
Dr. Eugene Schiff
Gastroenterology

Umhc-Sylvester Comprehensive Cancer Center

1475 NW 12th Ave, 
Miami, FL 
 (0.1 miles away)
305-243-1000
Languages Spoken:
English
See accepted insurances

Eugene Schiff is a Gastroenterologist in Miami, Florida. Dr. Schiff is highly rated in 9 conditions, according to our data. His top areas of expertise are Hepatitis, Hepatitis C, Nonalcoholic Steatohepatitis (NASH), Hepatitis B, and Liver Transplant.

Frequently Asked Questions about Dr. Cynthia Levy

How do I make an appointment with Dr. Cynthia Levy?

You can book an appointment with Dr. Cynthia Levy by calling their office at 305-689-1800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Cynthia Levy a top-rated expert for Primary Biliary Cholangitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Cynthia Levy is classified as an Elite expert for Primary Biliary Cholangitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Cynthia Levy specialize in?

While Dr. Cynthia Levy is a Gastroenterology, they have specific expertise in Primary Biliary Cholangitis, Cholangitis, and Sclerosing Cholangitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Cynthia Levy participate in research or clinical trials?

Yes. Dr. Cynthia Levy has published 167 articles and abstracts on conditions like Primary Biliary Cholangitis. You can view a list of Dr. Cynthia Levy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Cynthia Levy accept my insurance?

Dr. Cynthia Levy accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 305-689-1800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Levy's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile